Histomorphometric evaluation of the Ki-67 proliferation rate and CD34 microvascular and D2-40 lymphovascular densities drives the pulmonary typical carcinoid outcome

Imagem de Miniatura
Arquivos
art_VILHENA_Histomorphometric_evaluation_of_the_Ki67_proliferation_rate_and_2018.PDF (1.91 MB)
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2018
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
W B SAUNDERS CO-ELSEVIER INC
Autores
VILHENA, Alyne Fonseca de
PEREIRA, Joao Carlos das Neves
PARRA, Edwin Roger
ABRANTES, Marcelo Militao
Citação
HUMAN PATHOLOGY, v.81, p.201-210, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Ki-67 has shown promise as a prognostic factor in pulmonary carcinoids. In this study, we sought to validate the importance of Ki-67 and study the relationships between Ki-67 and other stromal biomarkers of vascular density. We examined Ki-67, CD34, and D2-40 in tumor tissues from 128 patients with surgically excised typical carcinoid of the lung. We used immunohistochemistry and morphometry to evaluate the amount of tumor staining for cellular proliferation (Ki-67), microvascular density (CD34-MVD), and D2-40 lymphovascular density. The main outcome was overall survival, considered as life expectancy until death from metastasis. Specimens from patients with central tumors showed high CD34-MVD (P = .01), which was also significantly associated with a compromised surgical margin, lymph node metastasis, and clinical stage Ib. Equally significant was high D2-40 lymphovascular density in central specimens with a compromised surgical margin and lymph node metastasis. A high Ki-67 proliferation rate was significantly associated with tumors from patients with clinical stage IIb, IIIa, and IV disease. Multivariate Cox model analysis demonstrated that tumor location and stage, surgical margin, tumor size, and N stage were significantly related to survival time (P < .05). Quantitative staining of the tumor for Ki-67 and CD34-MVD served as prognostic factors (P < .05), which were more relevant than the surgical and pathological stage. Ki-67 greater than 5% and CD34-MVD greater than 7% staining comprise a subset of patients with higher death hazard; this outcome may harbor evidence for further prospective studies of target therapy after surgical resection.
Palavras-chave
Carcinoid tumors, Morphometry, Ki-67 index, CD34, D2-40, Survival
URI
https://observatorio.fm.usp.br/handle/OPI/30069
Referências
  1. Abdalla SA, 1999, ONCOL REP, V6, P839
  2. Al-Khafaji B, 1998, HUM PATHOL, V29, P992, DOI 10.1016/S0046-8177(98)90206-4
  3. Anthony LB, 2010, PANCREAS, V39, P767, DOI 10.1097/MPA.0b013e3181ec1261
  4. Basavanhally AN, 2010, IEEE T BIO-MED ENG, V57, P642, DOI 10.1109/TBME.2009.2035305
  5. Basturk O, 2015, AM J SURG PATHOL, V39, P683, DOI 10.1097/PAS.0000000000000408
  6. Beasley NJP, 2002, CANCER RES, V62, P1315
  7. Breiteneder-Geleff S, 1999, AM J PATHOL, V154, P385, DOI 10.1016/S0002-9440(10)65285-6
  8. Brown LM, 2018, ANN THORAC SURG, V105, P207, DOI 10.1016/j.athoracsur.2017.07.049
  9. Clay V, 2017, CLIN TRANSL ONCOL, V19, P579, DOI 10.1007/s12094-016-1568-z
  10. COSTES V, 1995, HUM PATHOL, V26, P740, DOI 10.1016/0046-8177(95)90221-X
  11. Daddi N, 2014, EUR J CARDIO-THORAC, V45, P677, DOI 10.1093/ejcts/ezt470
  12. El-Gohary YM, 2008, AM J CLIN PATHOL, V129, P578, DOI 10.1309/2HGNJ1GU57JMBJAQ
  13. Erovic BM, 2005, WIEN KLIN WOCHENSCHR, V117, P53, DOI 10.1007/s00508-004-0298-3
  14. Faggiano A, 2008, J ENDOCRINOL INVEST, V31, P216, DOI 10.1007/BF03345593
  15. Fernandez-Cuesta L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4518
  16. FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4
  17. Folkman J, 2003, EXS, V79, P1
  18. Grimaldi Franco, 2011, Front Endocrinol (Lausanne), V2, P20, DOI 10.3389/fendo.2011.00020
  19. Guldhammer B, 2010, J THORAC ONCOL, V5, P453, DOI 10.1097/JTO.0b013e3181ca063b
  20. GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x
  21. Hall FT, 2003, ARCH OTOLARYNGOL, V129, P716, DOI 10.1001/archotol.129.7.716
  22. Karpanen T, 2001, J EXP MED, V194, pF37, DOI 10.1084/jem.194.6.F37
  23. Klimstra DS, 2010, AM J SURG PATHOL, V34, P300, DOI 10.1097/PAS.0b013e3181ce1447
  24. Liang L, 2018, ONCOTARGET, V9, P5406, DOI 10.18632/oncotarget.23526
  25. Lin HT, 2013, MOL VIS, V19, P166
  26. Ling SQ, 2012, ARCH OPHTHALMOL-CHIC, V130, P735, DOI 10.1001/archophthalmol.2012.293
  27. Liu SZ, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0174-z
  28. Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672
  29. Marion-Audibert AM, 2003, GASTROENTEROLOGY, V125, P1094, DOI 10.1053/S0016-5085(03)01198-3
  30. Marks A, 1999, BRIT J CANCER, V80, P569, DOI 10.1038/sj.bjc.6690393
  31. Matsumoto K, 2007, DIS COLON RECTUM, V50, P308, DOI 10.1007/s10350-006-0792-y
  32. Maula SM, 2003, CANCER RES, V63, P1920
  33. Meijer-Jorna LB, 2007, J CLIN PATHOL, V60, P798, DOI 10.1136/jcp.2006.038885
  34. Nassif Aissar Eduardo, 2010, Rev. Col. Bras. Cir., V37, P338, DOI 10.1590/S0100-69912010000500006
  35. Nathanson SD, 2003, CANCER, V98, P413, DOI 10.1002/cncr.11464
  36. Neder L, 2004, CLIN NEUROPATHOL, V23, P262
  37. Pathmanathan N, 2013, J CLIN PATHOL, V66, P512, DOI 10.1136/jclinpath-2012-201085
  38. Quinn AM, 2017, AM J SURG PATHOL, V41, P263, DOI 10.1097/PAS.0000000000000767
  39. Reid MD, 2015, MODERN PATHOL, V28, P686, DOI 10.1038/modpathol.2014.156
  40. Rindi G, 2006, VIRCHOWS ARCH, V449, P395, DOI 10.1007/s00428-006-0250-1
  41. Rindi G, 2014, ENDOCR-RELAT CANCER, V21, P1, DOI 10.1530/ERC-13-0246
  42. Ruben I, 2010, DIAGN CYTOPATHOL, V38, P217, DOI 10.1002/dc.21180
  43. Rugge M, 2008, CLIN CANCER RES, V14, P149, DOI 10.1158/1078-0432.CCR-07-1631
  44. Swarts DRA, 2017, HISTOPATHOLOGY, V70, P412, DOI 10.1111/his.13096
  45. Tang LH, 2016, CLIN CANCER RES, V22, P1011, DOI 10.1158/1078-0432.CCR-15-0548
  46. Thunnissen E, 2017, J THORAC ONCOL, V12, P334, DOI 10.1016/j.jtho.2016.12.004
  47. Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630
  48. Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221
  49. Uzzan B, 2004, CANCER RES, V64, P2941, DOI 10.1158/0008-5472.CAN-03-1957
  50. Van den Eynden GG, 2006, BRIT J CANCER, V94, P1643, DOI 10.1038/sj.bjc.6603152
  51. Walts AE, 2012, MODERN PATHOL, V25, P1258, DOI 10.1038/modpathol.2012.81
  52. Yildiz E, 2008, BJU INT, V101, P758, DOI 10.1111/j.1464-410X.2007.07318.x
  53. Zhang S, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3338-x
  54. Zheng G, 2013, ACTA CYTOL, V57, P281, DOI 10.1159/000346394

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/03
Artigos e Materiais de Revistas Científicas - LIM/61
Carregar mais